Member Info for AquaeSulis01

Mol I guess I couldn't give a toss whether the website is bang up to date or not in the grand scheme of things, more concerned with Superdrug stocking the 70 plus stores that either have nil or the odd box of either axis-ac or axis-ps 3 months after the rollout for phase 1 was supposed to have happened and for the stock to be prominently displayed and promoted because that will make a real difference to the share price.

From the results RNS "Alyson Levett will join the Board as a new Non-Executive Director; she will also take on Chair of the Audit Committee from Dr Cathy Prescott." Stop nit picking mol

Well as you know elrico, I am expecting the Croda Royalties and slipped sales revenue for BTS to compensate for my anticipated SInger forecast contribution miss from Superdrug and hence the low bar total Singer £6.2M (£3.1M H/Y revenue) forecast to at least be met., hence the optimism.

With SA's track record for Results RNS's tempted to say I'll be happy if the share price doesn't go down but I'll take 12p off net's forecast and say 28p to reflect my view over how the Superdrug launch has actually gone

I know what you were doing Toyin, but equally I was trying to demonstrate that since SA joined the Market Cap has grown significantly despite the failure of axisbiotix-ps to generate meaningful revenue and Croda delivering 4 or 5 years later than SBTX expected. Pompey makes a valid point about the most recent sp action which reflects Mark D's own opinion about the value to come from the Company now that royalties are finally flowing and the revenue from the Acquisitions are contributing to fixed overhead recovery.

That said, there remain areas for concern and improvement, the Superdrug launch appears to be patchy, comms sporadic and the pause on all R&D now that the cash position has improved, revisited.

An equally ridiculous comparator by you Toyin. When SA joined in 2019 the sp was circa 16p and the m/c was a lot less because there were far fewer shares in issue. The date you selected in the covid era preceded tge hype leading upto the Axis trial at a time when just about every small caps sp was inflated because there were so many novice traders dipping their toes in as they were furloughed or "working from home"

But it doesn't stop the big companies from investing in weight loss jabs rather than alternative treatments. www.londonstockexchange.com/news-article/AZN/astrazeneca-agrees-obesity-and-t2d-deal-with-cspc/17437893

A new SBTX Patent Update has appeared on the US Patent Database which is a timely reminder of the still untapped potential of the lysate technology in the area of wound infection protection, and surface cleaning

" The invention claimed i 1. A method of preventing, managing, or treating a skin infection in a subject in need thereof, the method comprising administering to the skin of the subject a composition consisting of a protein fraction derived from a secretion or lysate of Lactobacillus rhamnosus GG, wherein the proteins in the protein fraction consist of subtilin biosynthesis protein C (SpaC), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), elongation factor TU (EF-Tu), enolase, and triosephosphate isomerase (TPT). 2. The method according to claim 1, wherein the compo- sition further comprises one or more exopolysaccharides. 3. The method according to claim 1, wherein the compo- sition further comprises one or more pharmaceutically or cosmetically acceptable ingredients or excipients. 4. The method according to claim 1, wherein the infection is a Staphylococcus infection. 5. The method according to claim 4, wherein the infection is an S. aureus infection. 6. A method of preventing, managing, or treating a skin infection in a subject in need thereof, the method comprising administering to the skin of the subject a composition consisting of subtilin biosynthesis protein C (SpaC), glyc- eraldehyde-3-phosphate dehydrogenase (GAPDH), elonga- tion factor TU (EF-Tu), enolase, and triosephosphate isomerase (TPI)"

What is the best skincare product you have ever used?” This is the question I posed to the Vogue editorial team.

It’s not an easy one to answer. It’s a big ask that really got the editors scratching their heads. I want to know the ones they’ll replace for a straight swap. The ones they’ll cut open and eke out every last drop. The ones they’ll ration just to make them last that extra bit longer.

“A good skincare product supports and enhances skin health and optimises the appearance of the skin,” Dr Emma Wedgeworth, consultant dermatologist for AxisBiotix, tells us succinctly.

The skincare industry is constantly evolving, and new formulas are revealed each and every day. Which are the ones that transcend the notion of trend and have remained stalwarts since their launch?

What are the biggest misconceptions people have about the best skincare products?

Consultant dermatologist Dr Emma Wedgeworth tells us that people fail to consider the bigger picture. “Skincare is not just about creams,” she stresses. “Looking after your skin health needs an inside-out approach. Diet, lifestyle and a healthy gut are all very important, and probiotic supplements such as AxisBiotix can be very helpful to complement a skincare routine.” She also advises managing expectations and being cautious that just because something works for someone, it may not always work for you. “There is no one ‘wonder’ product,” she believes. “We need to find products that suit our own skin’s physiology.”

https://www.vogue.co.uk/article/best-skincare-products-reviewed#misconceptions

Not sure there is any mileage at all in rushing out a zenakine based product in advance of the VIPs launching. Better to piggy-back on the marketing that will accompany a major launching rather than trying to promote ourselves after all, Scandia Cosmetics launching in the backwaters of Poland with little publicity have generated only a handful of sales so far. Anyway, what Dermatonic product did you have in mind, something for tired feet in the once heel balm? :)

Beluga, having been here long enough to remember the previous axisbiotix stock write-off which followed a late change of strategy to sell ourselves rather than take lower margins with a partner, I am keen that history does not repeat itself. Now SA reads these boards, and I have previously supplied him with the raw data, so irrespective of what Superdrug are telling him about the rollout progress, it wont do any harm for him to have independent information on the number of stores showing Nil Stock at this stage of the rollout s that he can take any remedial action as he sees fit or not if all is well

Net, generally true. What I would say is that 72 Stores have shown No Stock of axisbiotix-ac (a number have stock of axisbiotix-ps) from day 1, so whilst they may have the odd box not accounted for on the shelf, I would be inclined to discount them from any calculations you make for weekly sales of the product.

I'm not missing any point. The data is for axisbiotix-ac only where you do not have a Customer for life as acne does not tend to be a lifelong ailment. Also, the stock carries a 2 year shelflife so will have to be written off if unsold within that period. Bit more analysis, I make no comment over how I think the rollout is progressing and leave it to others to interpret as they see fit:

Bit more analysis for the 5 week period between 20/12/25 and 24/01/26;

8 Stores have moved from NO Stock to Low Stock or In Stock

4 Stores have moved from Low Stock to NO Stock inferring stock of axisbiotix-ac has actually been sold in those stores

10 Stores have moved from Low Stock to In Stock

2 Stores moved from In Stock to Low stock inferring stock of axisbiotix-ac has actually been sold in those stores

The remaining 156 Stores show unchanged stock positions over the last 5 weeks

Generally yes clio, but answering net's specific request, I think it is fair to assume if a Store has gone from In-Stock to Low-Stock that some product has been sold

Net, just 2 stores, Crewe Grand Ju and Denton Crownpoint have gone from In Stock to Low Stock from which you can infer sales of the axisbiotix-ac product

Clio, three of the In Stock Stores for axisbiotix-ac; Nottingham Chilwell IN STOCK, Oxford Templers Sp IN STOCK, Oxford Westgate IN STOCK

For Axisbiotix-ac only, the 20th Dec 25 position was; In Stock = 27 stores, low Stock = 73 Stores and No Stock = 80 . Today the position is; In Stock = 42, Low Stock = 62 and No Stock = 76.

Bear in mind, No Stock does not necessarily mean No Stock but just the odd box on the shelf.

A reminder from my 10th Jan post:

"Hi ox, whilst I am not expecting early fireworks from the Superdrug launch, it is worth bearing in mind that Singer in their Broker note using a low estimate forecast sales of 3 boxes of axisbiotix-ac and 3 boxes of axisbiotix-ps per week at £30 per box in each of the 200 Stores rolled out in phase 1.

In practise, there were circa 182 Stores in phase 1, the rollout commenced in October but by December all but 40 of the Stores either stocked Axisbiotix-ps or Axisbiotix-ac with most stocking both. How do I know this? For every Store I used the collect 1 box at the Store option for each location we were told was included in phase 1. The sale price would also have been at the offer of £23 per box rather than £30 so i have based my uplifted axis calcs on this"

Now I have started to revisit the position as at today for ALL stores for comparison and whilst a few stock positions have changed it largely paints a static picture. One thing to bear in mind is that NO Stock does not actually mean NO Stock, just that there is only an odd box on the shelf that is not on the stock reservation system, I know this because Weston-Super-Mare had just 1 box each of Axisbiotix-ac and Axisbiotix-ps yet showed no stock on the collect at store on-line for the location. The boxes were at ankle level with no signage so you would need to be actively looking for the boxes to find them

"AquaeSulis01, I suspect that many PIs, including me, bought SBTX shares without having much faith in the management. " Not sue that's strictly true in your case is it shychap? You bought your shares when you had faith in the Management and continue to hold which is fair enough. Toyin did the same for most of his holding but then added recently despite his reservations which is what I queried. After all, if you believe it is all about Croda and that there is a risk the SBTX Strategy will reduce potential returns, then why not just buy Croda shares, enjoy the dividends and remove the risk?

Toyin, like you I want to see the Company sweat the assets it already has, which includes restarting some of the promising R&D Projects that have currently been halted, rather more acquisitions. That said, Beluga is spot on when he questions your logic in adding to your already overweight holding in this stock if you have no faith in the Management or their Strategy, it quite simply makes no sense

And many of us don't or no longer subscribe to TW who is not a shareholder of SBTX and already proven he lets his emotions rule his head so referencing his posts behind a paywall is pointless